U.S. Patent Granted

June 9th 2020, the United States Patent and Trademark office (USPTO) announced that Ossiform®’s patent, Feedstock for 3D printing and uses thereof no. PCT/DK2016/050323, has been granted in the USA.

This marks Ossiform®’s second patent issuance, following the approval and publication of its European patent, EP/3359318, in April 2020.

The patent covers the Company’s disruptive 3D printing technology that involves a novel bio-ink of powder particles suspended in a solid but meltable fatty acid matrix. The technology facilitates a new additive manufacturing process where objects are constructed directly from a computer-aided design (CAD) file.

Ossiform® will use this new way of 3D printing to enable the creation of P3D Bone, a unique patient specific implant with controlled internal voids and porosities, that allow for optimized bone ingrowth with wide-ranging benefits for patients needing bone repair.

The proprietary technology is currently used to produce and supply P3D Scaffolds, 3D printed bone models for in vitro and in vivo research wherein disease mechanisms can be studied and new treatments can be tested.

​

About Ossiform®

Ossiform® is a Danish MedTech company founded on proprietary technology to 3D print patient-specific, natural and resorbable bone implants. This enables faster ingrowth on bone tissue, remodeling into real living bone, and results in fewer complications. The technology can also be used for 3D printed R&D products, implants with additives, such as antibiotics or other drugs, and even in industries outside healthcare. Website: Ossiform – We Print Bone.